Scorpius Holdings, Inc.

NYSEAM:SCPX Stock Report

Market Cap: US$2.1m

Scorpius Holdings Valuation

Is SCPX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SCPX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SCPX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SCPX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SCPX?

Key metric: As SCPX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SCPX. This is calculated by dividing SCPX's market cap by their current revenue.
What is SCPX's PS Ratio?
PS Ratio0.2x
SalesUS$10.04m
Market CapUS$2.06m

Price to Sales Ratio vs Peers

How does SCPX's PS Ratio compare to its peers?

The above table shows the PS ratio for SCPX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.2x
FRTX Fresh Tracks Therapeutics
0.5xn/aUS$4.3m
TRVN Trevena
2.7x-6.1%US$1.5m
MRZM Marizyme
16.3xn/aUS$5.9m
CYCC Cyclacel Pharmaceuticals
9.5x82.9%US$685.6k
SCPX Scorpius Holdings
0.2x50.1%US$2.1m

Price-To-Sales vs Peers: SCPX is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (7.2x).

Price to Sales Ratio vs Industry

How does SCPX's PS Ratio compare vs other companies in the US Biotechs Industry?

129 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.9.7x21.3%
SCPX Scorpius Holdings
 0.2x50.1%US$2.06m
GILD Gilead Sciences
4x2.4%US$111.86b
BIIB Biogen
2.4x1.3%US$23.03b
SCPX 0.2xIndustry Avg. 9.7xNo. of Companies129PS01632486480+
129 CompaniesEstimated GrowthMarket Cap
Industry Avg.9.7x28.4%
SCPX Scorpius Holdings
 0.2x75.2%US$2.06m
No more companies

Price-To-Sales vs Industry: SCPX is good value based on its Price-To-Sales Ratio (0.2x) compared to the US Biotechs industry average (9.6x).

Price to Sales Ratio vs Fair Ratio

What is SCPX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SCPX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.2x
Fair PS Ratio6.3x

Price-To-Sales vs Fair Ratio: SCPX is good value based on its Price-To-Sales Ratio (0.2x) compared to the estimated Fair Price-To-Sales Ratio (6.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

7D

5.3%

1Y

17.0%

Collegium Pharmaceutical

US$980.7m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$29.96

7D

1.3%

1Y

15.1%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$56.91

7D

0.6%

1Y

9.8%